Gilead’s next steps in oncology

Whether Gilead is now a cancer company is in the eye of the beholder. By its own reckoning, the biopharma, which made its name in infectious disease, is about halfway on the path to its goal for oncology. 

CMO Merdad Parsey believes Gilead Sciences Inc. (NASDAQ:GILD) still needs to invest in its early cancer pipeline to make it a sustainable oncology company over the long term, a position he outlined on The BioCentury Show last month. Much of this focus will come from business development activity across a subset of biology areas...